Dr. Seymour on Investigational BTK Inhibitors in CLL

Erlene Seymour, MD, discusses investigational BTK inhibitors in chronic lymphocytic leukemia.

Erlene Seymour, MD, an assistant clinical professor at Wayne State University School of Medicine and a hematologist/oncologist at Barbara Ann Karmanos Cancer Institute, discusses investigational BTK inhibitors in chronic lymphocytic leukemia (CLL).

Currently, BTK inhibitors, such as tirabrutinib, are being evaluated for patients with CLL, says Seymour. Additionally, BTK inhibitors, such as LOXO-305 and vecabrutinib, have the potential to overcome BTK resistance mutations, Seymour explains.

As more agents are introduced to the landscape, a similar challenge regarding treatment selection may be faced with BTK inhibitors as is the case in chronic myeloid leukemia with TKIs, Seymour says. As these drugs continue to advance through the CLL pipeline, the field can better assess the toxicities associated with these agents to inform treatment selection for patients with CLL, concludes Seymour.